FibroGen Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de FibroGen han disminuido a una tasa media anual de -12.1%, mientras que en la industria Biotechs los beneficios crecieron en un 19.1% anualmente. Los ingresos han ido disminuyendo a una tasa media de 9.9% al año.

Información clave

-12.1%

Tasa de crecimiento de los beneficios

-10.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-9.9%
Rentabilidad financiera	n/a
Margen neto	-67.7%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

Desglose de ingresos y gastos

Cómo gana y gasta dinero FibroGen. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:FGEN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	180	-122	104
30 Jun 24	174	-168	112
31 Mar 24	167	-240	121
31 Dec 23	148	-284	132
30 Sep 23	155	-294	142
30 Jun 23	131	-322	146
31 Mar 23	116	-307	146
31 Dec 22	141	-294	142
30 Sep 22	123	-362	136
30 Jun 22	263	-220	132
31 Mar 22	258	-281	134
31 Dec 21	235	-290	135
30 Sep 21	284	-215	131
30 Jun 21	172	-231	57
31 Mar 21	190	-183	88
31 Dec 20	176	-189	108
30 Sep 20	119	-229	115
30 Jun 20	108	-311	200
31 Mar 20	257	-110	163
31 Dec 19	257	-77	135
30 Sep 19	357	42	103
30 Jun 19	353	49	82
31 Mar 19	205	-90	70
31 Dec 18	213	-86	64
30 Sep 18	136	-141	60
30 Jun 18	147	-123	57
31 Mar 18	133	-132	56
31 Dec 17	131	-121	52
30 Sep 17	132	-121	50
30 Jun 17	122	-121	49
31 Mar 17	181	-64	46
31 Dec 16	183	-58	46
30 Sep 16	172	-79	46
30 Jun 16	162	-100	46
31 Mar 16	193	-67	45
31 Dec 15	181	-86	44
30 Sep 15	172	-85	44
30 Jun 15	167	-79	43
31 Mar 15	136	-98	41
31 Dec 14	138	-60	37
30 Sep 14	134	-24	32
30 Jun 14	191	43	29
31 Mar 14	117	-5	26
31 Dec 13	102	-15	24

Ingresos de calidad: FGEN actualmente no es rentable.

Margen de beneficios creciente: FGEN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: FGEN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 12.1% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de FGEN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: FGEN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: El pasivo de FGEN supera su activo, por lo que es difícil calcular su rentabilidad financiera.

FibroGen Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Consensus estimates of losses per share improve by 17%

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40